Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.47 Analyst target: $4.00 Upside: 61.94%
Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare diseases caused by single gene defects. The company is headquartered in San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.